Medifast Inc (MED) · Oct 26, 2026 · Earnings

Medifast earnings beat estimates as coach count keeps collapsing

Beat — Adjusted EPS $(0.19) vs roughly $(0.35) consensus

Medifast’s Q3 earnings beat adjusted EPS expectations, but revenue fell 19% as active coaches nearly halved and GLP-1 pressure persisted.

Medifast is in the execution phase of its pivot from traditional coach-led weight loss toward Trilivy, a broader metabolic-health system, while GLP-1 adoption continues to pressure client acquisition and the coach network. The company has launched the new brand, products, compensation plan, and Coach Hub, but the turnaround still depends on rebuilding coach growth.

MetricQ3 2026Q3 2025 / expectation
Revenue$72.0M$89.4M prior year; roughly $71.3M consensus
GAAP diluted EPS$(1.57)$(0.21) prior year
Adjusted diluted EPS$(0.19)Roughly $(0.35) consensus
Active earning coaches10,20019,500 prior year
Adjusted EBITDA excluding interest$1.9M$1.7M prior year
Cash, cash equivalents and investments$172.5M$167.3M at Dec. 31, 2025

The quarter technically beat expectations, but mainly because the comparison is against a still-low bar. Revenue of $72.0 million was slightly above the published consensus of roughly $71.3 million, while adjusted loss per share of $0.19 was better than the roughly $0.35 expected. The GAAP loss was much worse because Catalyst restructuring charges added $15.4 million to the quarter; excluding those charges, the loss narrowed to $2.1 million, or $0.19 per diluted share.

The underlying customer-acquisition engine remains the central problem. Revenue fell 19.4% year over year as active earning coaches dropped 47.7% to 10,200, and management expects that count to keep declining through the end of 2026. 〔0〕 Higher revenue per remaining coach—$7,064 versus $4,585—shows better productivity among the survivors, but it has not offset the shrinking network. This is the key reason the earnings beat does not yet amount to evidence that the Trilivy strategy is working at scale.

The cost reset is producing a cleaner base, but it also exposed how far sales have fallen. Catalyst charges drove the reported operating loss to $19.4 million from $4.1 million a year earlier, while adjusted operating loss improved modestly to $4.0 million. Adjusted EBITDA excluding interest income rose only to $1.9 million from $1.7 million, so the quarter shows cost containment more clearly than a genuine revenue recovery.

Management is still targeting fourth-quarter profitability, but that forecast is now the main proof point for the turnaround. Q4 guidance calls for revenue of $55 million to $75 million, income per share of $0.00 to $0.25, and adjusted EBITDA excluding interest income of $2 million to $6 million. The balance sheet gives Medifast time to execute—with $172.5 million of cash, cash equivalents and investments and no debt—but it does not solve the shrinking coach base.

Bottom line: This is an adjusted earnings beat with a still-deteriorating core network. Medifast is buying time through restructuring and stronger productivity from remaining coaches, but Q4 profitability must arrive while coach attrition continues for the pivot to become credible.

What to watch next

Q4 2026 results and profitability test

Original filing on SEC EDGAR

Medifast earnings beat estimates as coach count keeps collapsing | MED Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.